Hormonal agents used in lowering lipoprotein(a)

Area of Science:

• Endocrinology
• Cardiovascular Medicine
• Lipid Metabolism

Background:

• Lipoprotein(a) (Lp(a)) is a quantitative genetic trait, with levels influenced by factors beyond genetics.
• Emerging data suggest sex hormones significantly modulate Lp(a) concentrations, particularly in women post-menopause.

Purpose of the Study:

• To evaluate the impact of estrogen/progestogen replacement therapy on Lp(a) and lipid levels in postmenopausal women.
• To determine the efficacy of hormone therapy in managing elevated Lp(a) and improving lipid profiles.

Main Methods:

• Assessed changes in plasma Lp(a) and lipid levels (total cholesterol, LDL-C, HDL-C) in postmenopausal women undergoing hormone replacement therapy.
• Monitored levels at 6 and 12 months, with follow-up one year after therapy cessation.

Main Results:

• Estrogen-progestogen therapy reduced mean Lp(a) levels by approximately 50% at 6 and 12 months.
• Therapy was most effective in women with initially high Lp(a) levels.
• Lp(a) levels returned to baseline one year post-therapy.
• Significant improvements in lipid profile: total cholesterol (-12%), LDL-C (-28%), HDL-C (+18%).

Conclusions:

• Sex hormones actively modulate Lp(a) metabolism, with both estrogen and progestogen exhibiting a lowering effect.
• Estrogen-progestogen treatment in postmenopausal women effectively lowers plasma Lp(a) and improves overall lipid profiles, suggesting cardiovascular benefits.